PentixaPharm
Phase 3Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It is committed to develop the innovative theranostic pair PentixaFor and PentixaTher, two small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor.
Founded
2014
Employees
51-200
Focus
DiagnosticsRadiopharmaceuticals
About
Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It is committed to develop the innovative theranostic pair PentixaFor and PentixaTher, two small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor.
Funding History
2Total raised: $27.5M
Series A$25MBoehringer Ingelheim Venture FundJun 15, 2021
Grant$2.5MGerman Federal Ministry of Education and ResearchMar 15, 2020
Company Info
TypePrivate
Founded2014
Employees51-200
LocationWürzburg, Germany
StagePhase 3
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile